Global Oncology | Specialty

The OncLive® Global Oncology condition center page is a comprehensive resource for clinical news and international expert insights on treatment of patients with cancer. This page features articles focused on ex-US regulatory news, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing global research in oncology care.

Olvi-Vec Plus Chemo Yields Disease Control in Platinum-Relapsed or -Refractory ES-SCLC

March 25th 2025

Olvi-vec plus chemotherapy led to disease control in extensive-stage small cell lung cancer that was relapsed/refractory to platinum chemotherapy.

EMA to Review Application for Expanded Indication for Sugemalimab in Unresectable NSCLC

March 24th 2025

A Type II variation application has been submitted to the EMA for the expanded approval of sugemalimab for unresectable stage III NSCLC.

NMPA Approves sNDA for Toripalimab Plus Bevacizumab in Advanced HCC

March 24th 2025

The combination of toripalimab and bevacizumab has been approved in China for the treatment of patients with unresectable or metastatic HCC.

Fruquintinib/Sintilimab Generates Favorable PFS Outcomes in Advanced RCC

March 19th 2025

Second-line fruquintinib plus sintilimab improved PFS, ORR, and DOR outcomes vs everolimus or axitinib monotherapy in advanced/metastatic RCC.

HER2DX Affects Approximately 50% of Treatment Decisions for HER2+ Breast Cancer

March 18th 2025

HER2DX aided in HER2+ breast cancer therapy decisions and the pCR rate was comparable among those who did and did not have HER2DX-driven treatment changes.

Penpulimab Gains NMPA Approval for First-Line Treatment of Recurrent or Metastatic NPC

March 18th 2025

Penpulimab received NMPA approval for first-line use with chemotherapy in recurrent or metastatic nasopharyngeal carcinoma.

Durvalumab Secures EU Approval for LS-SCLC After CRT

March 17th 2025

The European Commission approved durvalumab for limited-stage small cell lung cancer without disease progression following chemoradiation.

The OncFive: Top Oncology Articles for the Week of 3/9

March 15th 2025

Vepdegestrant boosts PFS in select ESR1-mutated breast cancer, maintenance OSE2101 combination provides survival benefit in PDAC, and more from OncLive.

Liso-Cel Receives European Approval in Relapsed/Refractory Follicular Lymphoma

March 14th 2025

The European Commission has approved liso-cel in relapsed/refractory follicular lymphoma after at least 2 prior lines of systemic therapy.

BLA Accepted in China for Tisotumab Vedotin in Recurrent/Metastatic Cervical Cancer

March 13th 2025

A BLA has been accepted in China seeking the approval of tisotumab vedotin for metastatic cervical cancer that has progressed on or after systemic therapy.

Imetelstat Earns EU Approval for Transfusion-Dependent Anemia in Lower-Risk MDS

March 12th 2025

The European Commission has approved imetelstat for the treatment of patients with transfusion-dependent anemia in lower-risk myelodysplastic syndrome.

Health Canada Approves Amivantamab/Lazertinib Combo for EGFR+ Advanced NSCLC

March 11th 2025

Amivantamab plus lazertinib was approved in Canada for first-line EGFR-mutated locally advanced or metastatic non–small cell lung cancer.

China’s NMPA Approves Sacituzumab Tirumotecan for Pretreated EGFR+ Advanced NSCLC

March 10th 2025

The Chinese NMPA has approved sacituzumab tirumotecan for EGFR-mutant advanced NSCLC following progression on an EGFR TKI and chemotherapy.

China’s NMPA Accepts MAA for Foritinib in ALK+ Advanced NSCLC

March 10th 2025

China’s NMPA has accepted an MAA seeking the approval of foritinib for ALK-positive advanced non–small cell lung cancer.

Nivolumab Plus Ipilimumab Receives EC Approval for First-Line Unresectable HCC

March 7th 2025

Nivolumab plus ipilimumab was approved by the European Commission for first-line, unresectable or advanced HCC.

Olverembatinib Plus Chemo Receives Breakthrough Therapy Designation in China for Newly Diagnosed Ph+ ALL

March 6th 2025

First-line olverembatinib plus low-intensity chemotherapy has received breakthrough therapy designation in China for patients with Ph-positive ALL.

Norway Grants Marketing Authorization to Illuccix PSMA-PET Imaging Agent in Prostate Cancer

March 5th 2025

NOMA has approved the PET imaging agent for the identification of PSMA-positive lesions in patients with prostate cancer.

Disparities in RCC Trial Access Illuminate the Need for Global Scientific Collaboration

March 3rd 2025

Regina Barragan-Carrillo, MD, discusses a study of RCC clinical trial availability and barriers to opening RCC clinical trials in lower-income countries.

CHMP Recommends Perioperative Durvalumab Regimen in Resectable NSCLC

March 3rd 2025

The CHMP has recommended the approval of perioperative durvalumab plus neoadjuvant chemotherapy for patients with resectable NSCLC.

CHMP Recommends Subcutaneous Daratumumab Plus VRd for Newly Diagnosed Myeloma

February 28th 2025

The CHMP has recommend the approval of subcutaneous daratumumab plus VRd for newly diagnosed multiple myeloma.